D. E. Shaw & Co. Inc. Has $28.82 Million Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

D. E. Shaw & Co. Inc. boosted its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 240.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 666,885 shares of the company's stock after purchasing an additional 471,111 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.71% of Scholar Rock worth $28,823,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC increased its stake in Scholar Rock by 103.4% during the third quarter. Barclays PLC now owns 165,449 shares of the company's stock worth $1,324,000 after acquiring an additional 84,118 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Scholar Rock by 17.6% during the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock worth $205,013,000 after buying an additional 708,817 shares during the last quarter. Principal Financial Group Inc. bought a new position in Scholar Rock during the 4th quarter worth approximately $274,000. Rhumbline Advisers raised its stake in Scholar Rock by 13.2% during the fourth quarter. Rhumbline Advisers now owns 113,261 shares of the company's stock worth $4,895,000 after acquiring an additional 13,247 shares during the period. Finally, Blackstone Inc. bought a new stake in shares of Scholar Rock in the 4th quarter worth approximately $910,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Wedbush reaffirmed an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a research note on Wednesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Scholar Rock has an average rating of "Buy" and an average price target of $42.67.

Scholar Rock Stock Down 2.7%

NASDAQ SRRK traded down $0.86 during trading on Wednesday, hitting $30.54. 1,298,022 shares of the company traded hands, compared to its average volume of 1,272,574. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The business has a fifty day simple moving average of $31.35 and a 200 day simple moving average of $35.87. The company has a market capitalization of $2.90 billion, a P/E ratio of -13.00 and a beta of 0.37. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). As a group, sell-side analysts predict that Scholar Rock Holding Co. will post -2.42 EPS for the current year.

Insider Buying and Selling at Scholar Rock

In other news, CFO Edward H. Myles sold 142,292 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the transaction, the chief financial officer now directly owns 111,345 shares of the company's stock, valued at $3,966,108.90. The trade was a 56.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mo Qatanani sold 68,510 shares of the company's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total value of $2,562,274.00. Following the transaction, the insider now directly owns 111,084 shares in the company, valued at approximately $4,154,541.60. This represents a 38.15% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 255,231 shares of company stock valued at $9,220,236. 13.30% of the stock is currently owned by corporate insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.